Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Psychiatric disorders

Targeting a PI3K subunit in schizophrenia

Nature Reviews Drug Discovery volume 11, page 602 (2012)Cite this article

Subjects

Access through your institution
Buy or subscribe

Genetic variations in the growth factor neuregulin 1 (NRG1) and in its receptor tyrosine kinase ERBB4 are associated with an increased risk of schizophrenia. Law et al. identified a signalling pathway regulated by schizophrenia-associated ERBB4 genotype, which involved increased expression of a phosphoinositide 3-kinase (PI3K)-linked ERBB4 receptor and the PI3K subunit p110δ. In rodent models, inhibition of p110δ using a small molecule prevented psychosis and reversed schizophrenia-related phenotypes, suggesting that p110δ could be a new target for the treatment of schizophrenia.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Law, A. J. et al. Neuregulin 1–ErbB4–PI3K signaling in schizophrenia and phosphoinositide 3-kinase–p110δ inhibition as a potential therapeutic strategy. Proc. Natl Acad. Sci. USA 11 Jun 2012 (doi:10.1073/pnas.1206118109)

    Article  CAS  Google Scholar 

Download references

Authors
  1. Charlotte Harrison
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, C. Targeting a PI3K subunit in schizophrenia. Nat Rev Drug Discov 11, 602 (2012). https://doi.org/10.1038/nrd3814

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd3814

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research